FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea FDA to Convene Pharmacy Compounding Advisory Committee in July Many people have stated that BPC 157 causes cancer because it promotes angiogenesis, the growth of new blood vessels. But angiogenesis is not automatically bad. Physiological angiogenesis is essential for survival. When you FDA mulls compounding for peptides previously flagged over safety risks BioSpace